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1314Salvage Allogeneic Hematopoietic Cell Transplantation
with Fludarabine and Low-Dose Total Body Irradiation
after Rejection of First Allografts
Boglarka Gyurkocza,1 Thai M. Cao,2 Rainer F. Storb,1 Thoralf Lange,3 Wendy Leisenring,1
Georg N. Franke,3 Mohamed Sorror,1 Richard Hoppe,2 David G. Maloney,1
Robert S. Negrin,2 Judith A. Shizuru,2 Brenda M. Sandmaier1We summarized results in 38 consecutive patients (median age5 56 years) with hematologic malignancies
(n5 35), aplastic anemia (n5 2), or renal cell carcinoma (n5 1), who underwent salvage hematopoietic
cell transplantation (HCT) for allograft rejection. In 14 patients, the original donors were used for salvage
HCT, and, in 24 cases, different donors were used. Conditioning for salvage HCT consisted of fludarabine
(Flu) and either 3 or 4 Gy total body irradiation (TBI). Sustained engraftment was achieved in 33 patients
(87%). Grafts were rejected in 5 patients (13%), 4 of whom had myelofibrosis. With a median follow-up
of 2 years (range: 0.3 to 7.8 years), the 2- and 4-year estimated survivals were 49% and 42%, respectively.
The 2-year relapse rate and nonrelapse mortality (NRM) were 36% and 24%, respectively. The 2-year cumu-
lative incidences of grades II-IV acute and moderate-severe chronic graft-versus-host disease (aGVHD,
cGVHD) were 42% and 41%, respectively. In this cohort, TBI dose, grafts from original versus different do-
nors, related versus unrelated donors, and HCT comorbidity scores did not have an impact on outcomes.
We concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using
conditioning with Flu and low-dose TBI.
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Graft rejection is an infrequent but life-threaten-
ing complication of allogeneic hematopoietic cell
transplantation (HCT), occurring historically at a fre-
quency of 6% or less after bone marrow transplanta-
tion (BMT) with myeloablative (MA) conditioning
[1,2]. However, with expanding indications for HCT
and widespread use of alternative donors and nonmye-
loablative (NMA) conditioning regimens, graft rejec-
tion rates of 12% to 15% have been reported [3-5].1Fred Hutchinson Cancer Research Center and the
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6/j.bbmt.2009.06.011Factors influencing graft rejection include underlying
diseases, previous chemotherapy, graft sources and
composition, degrees of HLA disparity, intensity of
conditioning regimens, and graft-versus-host disease
(GVHD) prophylaxis. In general, graft rejection has
been associated with poor outcome [6].
Management of graft rejection is challenging,
because of cytopenias, infections, and organ toxicity
resulting from the preparative regimens. Salvage allo-
geneic HCT represented a possible therapeutic strat-
egy, although the available literature has been limited
to small, single-institution series [7-12]. The early
experience with second allogeneic HCTs using MA
conditioning at the Fred Hutchinson Cancer Research
Center (FHCRC) was summarized by Radich et al.
[13]. Seventy seven patients with hematologic
malignancies underwent second allogeneic HCTs for
relapse after allogeneic marrow transplantation fol-
lowing high-dose chemotherapy and total-body irradi-
ation (TBI). In this series, patients older than 10 years
had a 60% risk of nonrelapse mortality (NRM) at 1
year. Second allogeneic HCTs were more successful
in patients with severe aplastic anemia (SAA), who
received cyclophosphamide (Cy)-based conditioning
Table 1. Patient Characteristics
Characteristics
Patients, n 38
Median age (range) in years 56 (8-68)
Sex, n (%)
Male 21 (55)
Female 17 (45)
Diagnosis, n (%)
AA/SAA 2 (5)
ALL 2 (5)
AML 12 (32)
CML 4 (11)
MPD/CIMF 6 (16)
MPD/MDS 3 (8)
MDS +/2 PNH 2 (5)
NHL 4 (11)
Plasma cell leukemia 1 (3)
MM 1 (3)
Renal Cell Ca 1 (3)
Patient CMV status, n (%)
negative 14 (37)
Biol Blood Marrow Transplant 15:1314-1322, 2009 1315Salvage HCTafter Rejection of First Allograftsregimens for both their first and second transplants
(10-year survival was 83% for patients undergoing
second HCT between 1982 and 1996) [14].
In general, secondMAHCT, particularly in adults,
has been associated with serious toxicities. For this rea-
son, reduced-intensity conditioning (RIC) regimens
were designed to escalate host immunosuppression
necessary for successful engraftment. Baron et al. [15]
described allogeneic HCTs after NMA conditioning
(2 Gy of TBI with or without fludarabine [Flu]) in pa-
tients who had experienced relapse after autologous
(n5 137) or allogeneic (n5 10)MAHCT.The overall
3-year NRM rate was approximately 30%.
Here we summarize the multicenter experience
with salvage allogeneic HCT in 38 patients with pri-
mary or secondary allograft rejection, using Flu and
TBI of 3 or 4 Gy as preparative regimen.positive 24 (63)
AA indicates aplastic anemia; ALL, acute lymphoblastic leukemia; AML,
acute myelogenous leukemia; CIMF, chronic idiopathic myelofibrosis;
CML, chronic myelogenous leukemia; CMV, cytomegalovirus; MM, mul-
tiple myeloma; MDS, myelodysplastic syndrome; MPD, myeloprolifera-
tive disorder; NHL, non-Hodgkin lymphoma; PNH, paroxysmal
nocturnal hemoglobinuria; SAA, severe aplastic anemia.PATIENTS AND METHODS
Patients
This retrospective analysis included 38 consecu-
tive patients with primary (n5 18) or secondary
(n5 20) allograft rejection who underwent salvage
allogeneic HCT after conditioning with Flu and
low-dose TBI (3 or 4 Gy) between March 2000 and
November 2007 at 3 participating centers: the
FHCRC (n5 16), Stanford University (SU; n5 11)
and the University of Leipzig (UL; n5 11). Primary
graft rejection was defined as failure to detect more
than 5% donor CD31 T cells in the peripheral blood
(PB) at any time point after HCT. Engraftment with
mixed chimerismwas defined as attainment of between
5% to 95% donor PB CD31 T cells at day 28. Follow-
ing initial engraftment, a decline in donor PB CD31 T
cells to#5%was considered secondary graft rejection.
Patients with evidence of relapse/progression of their
underlying disease following their first allograft were
not included in this study.
Results were analyzed as of July 28, 2008. Patient
characteristics are summarized in Table 1. Thirty-six
patients had failed 1, 1 patient had failed 2, and 1 patient
failed3preceding allogeneic transplants.Threepatients
had autologous HCTs before their first allogeneic
HCTs. There were 21 males and 17 females. Median
age of patients was 56 years (range: 8-68 years) with 1
exception, patients were older than 21 years. Diagnoses
included hematologic malignancies (acute myeloge-
nous leukemia, n5 12; myeloproliferative disorder
[MPD]/chronic idiopathic myelofibrosis, n5 6;
chronic myelogenous leukemia [CML], n5 4; non-
Hodgkin lymphoma [NHL], n5 4; myelodysplastic
syndrome [MDS]/overlap syndrome, n5 3; acute lym-
phoblastic leukemia, n5 2; MDS with or without
paroxysmal nocturnal hemoglobinuria, n5 2; multiple
myeloma (MM), n5 1; plasma cell leukemia, n5 1);aplastic anemia (AA), n5 2; and renal cell cancer
(RCC), n5 1.
A retrospective chart review and waiver of
informed consent for chart review were approved by
the institutional review boards of all 3 participating
Centers.First/Preceding HCTs
Characteristics of the first/preceding allogeneic
HCT are summarized in Table 2. With the exception
of the unrelated umbilical cord blood units (UCB),
patients and donors were tested for HLA-A, -B, -C,
and -DQB1 by at least intermediate-resolution DNA
typing and for HLA-DRB1 by high-resolution tech-
niques. Cord blood units were tested for HLA-A and
B antigens and DRB1 alleles. Grafts were from HLA-
identical siblings (n5 11), HLA-matched unrelated
donors (n5 17) and HLA-mismatched unrelated do-
nors (n5 10, including 2 patients who received double
unrelated UCB grafts). Additional details of HLA-dis-
parity, including the number of mismatched HLA loci
are summarized in Table 2. The stem cell sources were
granulocyte colony-stimulating factor (G-CSF)-mobi-
lized peripheral blood stem cell (PBSC; n5 32), BM
(n5 4), or UCB (n5 2). The median CD341 cell
dose for PBSC grafts was 7.67 106 CD 341 cells/kg
recipient weight. The median total nucleated cell
(TNC) count of BM and double UCB grafts were
1.55 108/ kg and 3.79 107/kg recipient weight, re-
spectively. A total of 28 patients received NMA condi-
tioning with 2 Gy TBI on day 0 with (n5 27) or
without (n5 1) Flu 30 mg/m2/day on days24 through
Table 2. Characteristics of First/Preceding HCT
Characteristics
Donor, n (%)
HLA-identical sibling 11 (29)
—matched unrelated 17 (45)
—mismatched unrelated 10 (26)
B-allele 3 (8)
C-antigen 3 (8)
C-antigen and C-allele 1 (3)
DRB1-allele 1 (3)
B-antigen/B-antigen (double UCB graft) 1 (3)
A- and B-antigen/A- and B-antigen
(double UCB graft)
1 (3)
ABO mismatch n (%)
Major 16 (42)
Minor 6 (16)
Stem cell source, n (%)
PBSC 32 (84)
Marrow 4 (11)
UCB 2 (5)
Cell dose
PBSC—Median CD34+ cell dose (range) 106/kg 7.67 (3.3-62)
Double UCB—Median TNC dose (range) 107/kg 3.79 (2.58-5.0)
Marrow—Median TNC dose (range) 108/kg 1.55 (1.18-2.6)
Conditioning, n (%)
Flu, TBI (2 Gy) 27 (71)
TBI (2 Gy) 1 (3)
Bu, Cy 6 (16)
Cy —TBI (12 Gy) 1 (3)
—Flu, ATG,TBI (2 Gy) 1 (3)
—ATG, TBI (4 Gy) 1 (3)
—ATG 1 (3)
GVHD prophylaxis, n (%)
MMF —CsA 29 (76)
—Tacrolimus 1 (3)
Methotrexate —CsA 4 (11)
—Tacrolimus 4 (11)
ATG indicates antithymocyte globulin; Bu, busulfan; CsA, cyclosporine
A; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host dis-
ease; HCT, hematopoietic cell transplant; MMF, mycophenolate mofetil;
PBSC, peripheral blood stem cell; TBI, total body irradiation; TNC, total
nucleated cell; UCB, umbilical cord blood.
Table 3. Characteristics of Salvage HCT
Characteristics
Median days (range) from prior HCT 91 (29-1004)
Donor, n (%)
Same as in prior HCT 14 (37)
Different from prior HCT 24 (63)
HLA-identical sibling 11 (29)
—haploidentical related 1 (3)
—matched unrelated 14 (37)
—mismatched unrelated 12 (32)
antigen (A: n5 1; C: n5 4) 5 (13)
allele (A: n5 1; B: n5 1; C: n5 1) 3 (8)
DRB1-allele 1 (1)
DRB1-allele, DQB1-allele 1 (3)
A-antigen, C-antigen, C-allele 1 (3)
A- and DRB1-antigen/A- and
DRB1-antigen (double UCB graft)
1 (3)
ABO mismatch, n (%)
Major 9 (26)
Minor 11 (28)
Stem cell source, n (%)
PBSC 36 (95)
Marrow 1 (3)
UCB 1 (3)
Cell dose
PBSC—Median CD34+ cell dose
(range) 106/kg
7.6 (1.5-19.39)
Marrow—TNC dose 108/kg 6.22
Double UCB—TNC dose 107/kg 4.0
Conditioning, n (%)
Flu—3 Gy TBI 24 (63)
—4 Gy TBI 12 (32)
—Cy, 4 Gy TBI 2 (5)
GVHD prophylaxis, n (%)
MMF—CsA 37 (97)
—Tacrolimus 1 (3)
HCT-CI at time of salvage HCT, n (%)
0-1 6 (16)
2-3 12 (32)
4-5 14 (37)
$6 6 (16)
CsA indicates cyclosporine A; Cy, cyclophosphamide; Flu, fludarabine;
GVHD, graft-versus-host disease; HCT, hematopoietic cell transplant;
MMF, mycophenolate mofetil; PBSC, peripheral blood stem cell; TBI,
total body irradiation; TNC, total nucleated cell; UCB, umbilical cord
blood.
1316 Biol Blood Marrow Transplant 15:1314-1322, 2009B. Gyurkocza et al.22. Seven patients received MA conditioning with bu-
sulfan (Bu) (n5 6) or 12 Gy fractionated TBI (n5 1)
combined with Cy. Three patients received
antithymocyte globulin (ATG) combined with either
Cy (n5 1), Cy/4 Gy TBI (n5 1), or CY/Flu/2 Gy
TBI (n5 1). Postgrafting immunosuppression for the
29 patients receiving NMA or ATG/low-dose TBI-
based conditioning consisted of mycophenolate mofe-
til (MMF) and cyclosporine (CsA), as described [16].
One patient givenNMA conditioning received tacroli-
mus and MMF. Patients undergoing MA conditioning
received methotrexate (MTX) and either CsA (n5 4)
or tacrolimus (n5 4), as described [17,18]. Following
HCT, patients weremonitoredwith daily blood counts
for evidence of engraftment. Donor chimerism was
evaluated in PB CD31 T cells and granulocytes
(CD331 cells at the FHCRC and CD151 cells at SU
and UL) separated by flow cytometry. Donor-host
chimerism levels were evaluated on day 28, and, for
most patients, on days 84, 180, and 360 after HCT
using polymerase chain reaction (PCR)-based amplifi-
cation of variable-number tandem repeat or short-tan-dem repeat sequences unique to donors and hosts, or by
fluorescein in situ hybridization (FISH) for X and Y
chromosomes in some cases when patients and donors
were sex mismatched.
Primary graft rejection was defined as inability to
detect more than 5% donor CD31 T cells in the PB
at any time point after HCT. Following initial engraft-
ment, a reduction in donor PB CD31 T cells to #5%
was considered secondary graft rejection, as detailed
earlier. Based on these definitions, 18 of 38 patients ex-
perienced primary graft rejection; the remaining 20
had secondary graft rejection.Second/Salvage HCTs
Characteristics of the second/salvage allogeneic
HCT are summarized in Table 3. HLA typing, patient
monitoring, and chimerism testing were carried out as
previously described. None of the patients included in
Biol Blood Marrow Transplant 15:1314-1322, 2009 1317Salvage HCTafter Rejection of First Allograftsthis analysis had evidence of relapse/progression of
their underlying disease at the time of salvage alloge-
neic HCT. Pretransplantation comorbidities were de-
termined retrospectively using an HCT-specific
comorbidity index (HCT-CI) [19]. Salvage HCTs
were performed at a median of 91 days (range: 29-
1004 days) after the preceding HCT. If patients had
HLA-identical sibling donors for their preceding
HCT, the same donors were used for salvage HCT,
depending on their availability. When patients had
HLA-matched unrelated donors (MUD) for their pre-
vious HCT, different donors were utilized for salvage
HCT, except in 3 patients. In summary, donors for the
second HCT were the same as for the first in 14 cases;
11 were HLA-identical siblings and 3 HLA-MUD. In
the remaining 24 cases different donors were used; 11
were HLA-MUD, 11 HLA-mismatched unrelated
(MMUD), 1 HLA-haploidentical related, and 1 dou-
ble UCB graft (Table 4). Additional details of HLA-
disparity, including the number of mismatched HLA
loci are shown in Table 3. The stem cell sources
were PBSC (n5 36), BM (HLA-haploidentical donor,
n5 1) or UCB (n5 1). The median CD341 cell count
for PBSC grafts was 7.6 106 CD 341 cells/kg recip-
ient weight, the TNC counts were 6.22 108/kg re-
cipient weight and 4.0 107/kg recipient weight for
the marrow and double UCB grafts, respectively.
The conditioning regimens consisted of Flu 30 mg/
m2/day on days 24 to 22, followed by 3 Gy TBI
(n5 24) or 4 Gy TBI (n5 12) on day 0. The determi-
nation of the TBI dose (3 versus 4 Gy) was center-de-
pendent. Except for 2 patients with HLA-identical
sibling donors, all patients treated at FHCRC received
4 Gy TBI. All patients treated at SU and at the UL re-
ceived 3 Gy TBI. One HLA-haploidentical recipient
received Flu, 30 mg/m2/day on days 26 to 22, Cy,
25 mg/kg on days 26 and 25, and 4 Gy TBI on day
21. Another patient given a double UCB graft was
conditioned with Flu, 40 mg/m2/day on days 26 to
22, Cy, 50 mg/kg on day 26, and 4 Gy TBI on day
21. Postgrafting immunosuppression for 37 patients
consisted of CsA and MMF, as described [16] and ta-
crolimus and MMF for 1 patient. Acute GVHD
(aGHVD) and chronic GVHD (cGVHD)were graded
as described [20,21]. Toxicities occurring within theTable 4. Donors in First and Second HCTs
First HCT Same Donor HLA- MURD
HLA-identical sibling 11 11 –
HLA-MUD 17 3 10
HLA-MMUD 8 – 1
Double UCB 2 – –
HLA-MMUD indicates HLA-mismatched unrelated donor; HLA-MUD, HLA-mfirst 100 days were scored using the Common Termi-
nology Criteria for Adverse Events v3.0.
Causes of Death
In patients who relapsed or progressed, relapse/
progression was listed as primary cause of death
regardless of other associated events. In patients with
GVHD requiring immunosuppressive therapy who
subsequently died from infections, GVHD/infection
was listed as cause of death. Infection was listed as
cause of death when it occurred in the absence of
relapse/progression or GVHD. All deaths occurring
in the absence of relapse/progression were considered
NRM.
Statistical Analysis
Summary statistics were reported using standard
measures as appropriate for categorical and continu-
ous data. The primary endpoint of this retrospective
analysis was engraftment. Secondary endpoints in-
cluded: overall survival (OS), NRM, relapse/progres-
sion, aGVHD, and cGVHD.
Overall survival was estimated using the Kaplan-
Meier method. Cumulative incidence estimates were
used for engraftment, relapse/progression, aGVHD
and cGVHD, and NRM, treating death prior to the
event of interest as a competing risk for engraftment,
relapse, and aGVHD, and relapse as a competing
risk event for NRM [22]. Associated 95% confidence
intervals (CIs) were calculated using Greenwood’s for-
mula for Kaplan-Meier estimates and the method
described by Marubini and Valsecchi [23] for cumula-
tive incidence. Comparisons between hazards of time
to event outcomes were compared using the logrank
test. All reported P-values were 2 sided and P-values
\.05 were considered significant.RESULTS
Engraftment
All patients experienced transient neutropenias.
Thirty-three of 38 patients (87%) had sustained en-
graftment, with a median time to neutrophilSecond HCT
Different Donor
HLA-MMURD Double UCB HLA- haploidentical
– – –
4 – –
7 – –
– 1 1
atched unrelated donor; UCB, umbilical cord blood.
1318 Biol Blood Marrow Transplant 15:1314-1322, 2009B. Gyurkocza et al.engraftment of 15 days (range: 9-42 days) (Figure 1A).
Chimerism data were available on 32 of 33 engrafted
patients. On day 128 after HCT, the median (range)
peripheral blood CD31 and CD331/CD151 cell chi-
merism levels were 98 (11-100)% and 100 (89-100)%,
respectively.
Five patients, 4 with myelofibrosis and 1 with ALL
rejected their grafts. Two of the 5 rejecting patients
had HLA-identical sibling donors, 2 had HLA-
MUD, and 1 had an HLA-A allele-MMUD. Three
of the 5 had the same donors as in their previous
HCT (2 HLA-identical siblings and 1 HLA-MUD),
whereas 2 patients had different donors (1 HLA-
MUD- and 1 HLA-A allele-MMUD). Four of the 5
patients received 3 Gy and 1, 4 Gy TBI as part of their
conditioning.GVHD
All patients were assessed for aGVHD. The cumu-
lative incidences of aGVHD, grades II-IV, III, and IV,
were42%,5%, and5%, respectively (Figure 2A).Of the
16 patients who developed grades II-IV aGVHD, 9 had
HLA-MMUD, 4 had HLA-MUD, 2 had HLA-identi-
cal sibling donors, and 1 anHLA-haploidentical related
donor. Moderate-severe cGVHD developed in 41% of
transplanted patients (Figure 2B.). Four of the 110
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Figure 1. Outcomes of salvage HCT. Neutrophil engraftment (A). Thirty-thr
0.87; 95% CI: 0.74, 0.95). The median time to neutrophil engraftment was 15 (ra
survival were 0.49 (95% CI: 0.31, 0.66) and 0.42 (95% CI: 0.23, 0.61), respective
0.11, 0.41). Relapse/progression (D). The estimated probability of relapse/pro
resent 95% CI.patients with cGVHD have successfully discontinued
systemic immunosuppressive therapy at a median
(range) of 2.5 (1.4-7.4) years, whereas 7 are still receiv-
ing immunosuppression.Nonhematologic Toxicities, NRM, and Causes
of Death
Table 5 summarizes nonhematologic toxicities
within the first 100 days. Multiple toxicities could be ac-
cumulated in a given patient. A total of 8 episodes of
severe nonhematologic toxicity occurred in 6 patients
within the first 100 days, with fatal outcome in 2 patients
(pneumonia and aGVHD with gastrointestinal (GI)
and liver involvement). The day 100 NRM was 5%.
There were 13 episodes of neutropenic fever, 17
episodes of documented bacteremia/sepsis, and 4 epi-
sodes of bacterial pneumonia, of which 1 was fatal
(Strenotrophomonas). Sixteen patients experienced
cytomegalovirus (CMV) reactivation, 1 patient devel-
oped CMV duodenitis, and 1 patient was diagnosed
with CMV pneumonitis, none of which was fatal.
The leading causes of NRM were GVHD (n5 3)
and infections (n5 3). One patient died of unknown
causes (this patient’s death was classified as NRM).
The estimated probability of NRM at 2 years was
24% (Figure 1C).0
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Figure 2. GVHD. Grades II-IV aGVHD (A). The cumulative incidence of grades II-IV aGVHD at day 100 was 0.42 (95% CI: 0.26, 0.57). The cumulative
incidences of grade III and grade IV aGVHDwere 0.05, each (95% CI: 0.009, 016). Moderate-severe cGVHD (B). The cumulative incidence of moderate-
severe cGVHD at 2 years was 0.41 (95% CI: 0.25, 0.57). The dashed lines represent 95% CI.
Biol Blood Marrow Transplant 15:1314-1322, 2009 1319Salvage HCTafter Rejection of First AllograftsRelapse/Progression
Thirteen of 38 patients (34%) experienced relapse/
progression, including 4 with AML, 4 with myelofi-
brosis, 2 with MPD/MDS, and 1 each with lymphoma
NHL, CML, and RCC. Ten of 13 patients died of re-
lapse/progression, which remained the leading cause
of death. The estimated probability of relapse/pro-
gression was 36% at 2 years (Figure 1D).Survival
The median follow-up among surviving patients
was 2.0 years (range: 0.7 to 7.8 years). The estimated
OS was 49% at 2 years and 42% at 4 years
(Figure 1B).Within the limitations of the small numberTable 5. Grades 3-5 Nonhematologic toxicities, infectious
complications, and causes of death
Grade
Characteristic 3 4 5
Nonhematologic toxicity at day 100 (events, n)
Cardiovascular 0 0 0
Gastrointestinal 1 0 0
Liver 0 0 1
Infectious 70 0 1
Metabolic 29 2 1
Neurologic 3 1 0
Pulmonary 6 1 1
Renal 2 0 0
Infectious complications at day 100 (events, n)
Febrile neutropenia 13 0 0
Nonneutropenic fever 13 0 0
Adenovirus viremia 1 0 0
Bacteremia/bacterial sepsis 17 0 0
Bacterial pneumonia 3 0 1
CMV reactivation 14 0 0
CMV duodenitis 1 0 0
CMV pneumonitis 1 0 0
Fungal pneumonia/infection 3 0 0
HHV6 reactivation 1 0 0
RSV/viral upper respiratory tract infection 3 0 0
Causes of death, n
Relapse/progression 10
GVHD with or without infection 3
Infection (pneumonia) 3
Unknown 1
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease; RSV,
respiratory syncytial virus.of patients studied, donor type did not have an impact
on OS in univariate analysis (Figure 3A). At 2 years
the estimated probability of survival for patients with
HLA-identical sibling donors was 44% (95% CI:
15%, 70%, n5 11), compared to 50% (95% CI: 21%,
73%; n5 14) for patients with HLA-MUD and 61 %
(95% CI: 27%, 84%; n5 13; P5 .98) for patients
who received either HLA-MMUD, HLA-haploidenti-
cal related or double UCB grafts.
Further, patients who received salvage HCT from
the original donor had outcomes similar to those with
different donors (Figure 3B), with a 2-year probability
of survival of 47% (95% CI: 19%, 71%; n5 14) com-
pared to 52% [95% CI: 27%, 72%, n5 25; P5 .86).
Also, estimated probabilities of 2-year survival of
patients receiving 3 or 4 Gy respectively, were compa-
rable (59% [95% CI: 35%, 76%; n5 24], and 38%
[95% CI: 13%, 63%; n5 14]; P5 .38; Figure 3C).
Finally, although therewas a trend towardworseOS
for patients with high HCTComorbidity Index scores,
this difference did not reach statistical significance in
univariate analysis (Figure 3D). Estimated 2-year prob-
ability of survival for patients with HCT-CI scores of
0-3 was 60% (95% CI: 30%, 81%; n5 17) compared
to 37% (95% CI: 15%, 60%) for patients with HCT-
CI scores of 4 or more (n5 21; P5 .16).DISCUSSION
Primary and secondary graft rejections have been
associated with poor prognosis. Because graft rejec-
tions are relatively uncommon, few studies have been
published that address management of this serious
complication. Rescue of patients with a salvage HCT
is a promising approach that could potentially provide
long-term survival; however, there has been no con-
sensus on donor selection or the nature of condition-
ing regimens.
An abstract from the 2008 Annual Meeting of the
American Society of Hematology summarizing data of
the Center for International Bone Marrow Transplant
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Figure 3. Impact of donor type (A), using same versus different donor (B), TBI dose (C), and HCT-CI score (D) for OS.
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donor transplants after primary non-engraftment rep-
resented the largest current dataset, with a disappoint-
ingly low OS of 11% and high (86%) treatment-
related mortality (TRM) at 1 year [24]. These results
might be explained, in part, by the use ofMS condition-
ing for second transplants in patients who had already
been heavily pretreated.
Similar findings were reported by Kedmi et al. [25]
in a single-institution analysis of salvage HCTs per-
formed between 1981 and 2007. In this cohort, 144 pa-
tients (median age 20.7 years) underwent salvage
allogeneic HCT, 62 of them for primary or secondary
graft rejection. The day 100 TRM was 45.5%, with
a 1-year OS of 20%. Twenty-three of 80 patients re-
ceiving an RIC regimen survived at 1 year compared
to 6 of 64 who received MA regimens, although the
specific regimens were not described.
Other, smaller series have described more encour-
aging results, but better outcomes seemed to be lim-
ited to pediatric patients [12,26,27].
Chewning et al. [10] reportedon16patientswho re-
ceived second allogeneic HCTs at a median of 45 days
following firstHCTs, using primarily Flu-based condi-
tioning in combination with Cy or thiotepa and added
ATG or alemtuzumab. These regimens resulted in an
impressive 100% engraftment rate. The OS at 3 years
was 35%, but, importantly, only 1 of 8 patients older
than 20 years survived more than 6 months.
Heinzelmann et al. [11] used total lymphoid irradi-
ation in conjunctionwith anti-T-lymphocyte antibodies(OKT3 and/or ATG) for second HCTs, after allograft
rejection or graft failure. Eleven of 14 patients engrafted
(78%).Among7 children, the 2 yearOS ratewas 85.7%,
with a very favorable toxicity profile. In contrast, noneof
the 7 adults survived beyond 200 days, with 6 dying of
nonrelapse causes.
Jabbour et al. [9] used Flu and ATG to condition 9
patients with allograft failure for secondHCT (median
age was 49 years). Six of the 9 (67%) engrafted, how-
ever, only 1 patient remained alive at last follow-up;
the high mortality rate was mainly because of aGVHD
and infections.
Moreencouragingoutcomeswere reportedbyByrne
et al. [8] in a study involving 11 adult patients undergoing
second HCT after graft rejection. The preparative regi-
men for second HCT consisted of Flu, Cy, and alemtu-
zumab. Nine patients (81%) engrafted. With a median
follow-up of 29 months 5 of the 11 patients were alive;
therewere2 treatment-relateddeaths,whereas 4patients
died of progressive disease (PD).
Although differences in patient and transplant
characteristics made direct comparison between the
above series difficult, some generalized conclusions
may be drawn. Many salvage transplants failed because
of high relapse- and NRM rates, the combined effects
of preexisting organ damage, more advanced disease,
and more profound immunosuppression associated
with the second preparative regimen. The intensifica-
tion of the immunosuppressive regimens promoted
engraftment, but led to higher rates of infections and
decreased graft-versus-tumor (GVT) effects. NMA
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comes than high-dose regimens, especially in adults.
In our study, conditioning with Flu and 3 or 4 Gy
TBI for salvage HCT was well tolerated and resulted
in an engraftment rate of 87%. The regimen was based
on our primaryNMA conditioning regimen for alloge-
neic HCT, which consisted of Flu and 2 Gy TBI [3].
The TBI doses 3 and 4 Gy used for our salvage regi-
men were slightly higher, and were selected for specific
reasons. The main components of engraftment resis-
tance have been immunmediated host-versus-graft
reactions [28]. The effector cells of these reactions,
the host T-lymphocytes are radiation sensitive. The
relationship between irradiation dose and cell killing
is nonlinear; thus, 3 or 4 Gy TBI likely eradicated
residual host immune cells that otherwise would have
mediated graft rejection [29,30]. Studies in DLA-iden-
tical littermate dogs have shown that augmentation of
immunosuppression by increasing TBI from 2 Gy to
4.5 Gy increased the rate of stable donor marrow en-
graftment from 0 to 41% in the absence of postgrafting
immunosuppression [31-33]. One fundamental differ-
ence between the various forms of anti-T-lymphocyte
antibodies (OKT3, ATG, or alemtuzumab) and TBI
was that whereas the former provided different degrees
of in vivo depletion affecting both host and donor
T-lymphocytes, TBI had an impact on only the host
immune system, leaving the incoming donor lympho-
cytes intact. TBI, therefore, allowed donor T cells to
exert the desired GVH effect both for overcoming en-
graftment barriers and control of underlying malig-
nancies.
With 1 exception, our analysis included adult
patients with primary or secondary allograft rejections.
Their median age was 56 years; only 1 patient in this
cohort was younger than 21 years, whereas the oldest
patient was 68 years old. The 2-year NRM associated
with our preparative regimen was 24%, which was
comparable to that seen after our standard NMA con-
ditioning regimen of Flu and 2 Gy TBI in the first
transplant setting [34,35]. Relapse has remained
a problem, highlighting the importance of the func-
tional preservation of donor T-lymphocytes to achieve
potent allogeneic GVT effects.
An interesting finding in this cohort was that 4 of
the 5 patients who failed salvage HCT were among 6
patients with myelofibrosis. Although this number
was too small to draw definitive conclusions, results
suggested that alternative conditioning regimens
should be developed for patients with myelofibrosis,
who have failed their first HCT. Graft rejection has
been a considerable problem in these patients after
other conditioning regimens as well [36].
Based on the current analysis, we concluded that
graft rejection following allogeneic HCT could be
effectively corrected by salvage transplantation using
conditioning with Flu and 3 or 4 Gy TBI, with resul-tant long-term survival in 40% to 50% of patients.
This treatment modality could be offered to older pa-
tients, to those lacking HLA-identical sibling donors
and to patients with comorbid conditions.AUTHORSHIP
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